Randomized, placebo-controlled, pilot clinical study evaluating acute Niagen®+ IV and NAD+ IV in healthy adults

Objective

To assess the safety and efficacy of a single intravenous administration of NR compared to NAD+ and a saline control in terms of whole blood NAD+ changes, tolerable infusion rates, and clinical chemistry safety profiles.

Study Design

Randomized, double-blind, placebo-controlled pilot clinical study in healthy adults.

The study included two phases, with data analyzed from 37 participants in the first phase and 16 participants in the second phase.

Dose

Single dose of 500 mg

Duration

24 hours

Key Outcomes

  • IV NR was safe, well-tolerated, and resulted in fewer and less severe adverse experiences compared to NAD+ IV.

  • NR IV increased NAD+ levels by 20.7% after three hours, outperforming both IV NAD+ and oral NR supplementation.

  • IV NR infusion time was 75% shorter than that of IV NAD+.

  • While IV NAD+ increased white blood cell and neutrophil counts, indicating a potential inflammatory response, IV NR showed no evidence of such a response.

Clinical, Intravenous, Pharmacokinetic/SafetyANAD Staff